Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc.
Decision Date | 20 June 2019 |
Docket Number | 2017-2498, 2017-2499, 2017-2545, 2017-2546 |
Citation | 928 F.3d 1340 |
Parties | ENZO LIFE SCIENCES, INC., Plaintiff-Appellant v. ROCHE MOLECULAR SYSTEMS, INC., Roche Diagnostics Corporation, Roche Diagnostics Operations, Inc., Roche Nimblegen, Inc., Becton, Dickinson and Company, aka Becton Dickson and Company, Becton Dickinson Diagnostics Inc., aka Becton Dickson Diagnostics, GeneOhm Sciences Inc., Abbott Laboratories, Abbott Molecular, Inc., Defendants-appellees |
Court | U.S. Court of Appeals — Federal Circuit |
Justin P.D. Wilcox, Desmarais LLP, New York, NY, argued for plaintiff-appellant. Also represented by John M. Desmarais ; Peter Curtis Magic, San Francisco, CA.
Matthew Wolf, Arnold & Porter Kaye Scholer LLP, Washington, DC, argued for defendants-appellees Roche Molecular Systems, Inc., Roche Diagnostics Corporation, Roche Diagnostics Operations, Inc., Roche NimbleGen, Inc., Becton, Dickinson and Company, Becton Dickinson Diagnostics Inc., GeneOhm Sciences Inc.
John C. O'Quinn, Kirkland & Ellis LLP, Washington, DC, argued for defendants-appellees Abbott Laboratories, Abbott Molecular, Inc. Also represented by Michael Pearson, Jason M. Wilcox ; James F. Hurst, Amanda J. Hollis, Chicago, IL; Benjamin Adam Lasky, New York, NY.
Omar Khan, Wilmer Cutler Pickering Hale and Dorr LLP, New York, NY, for defendants-appellees Roche Molecular Systems, Inc., Roche Diagnostics Corporation, Roche Diagnostics Operations, Inc., Roche NimbleGen, Inc., Becton Dickinson and Company, Becton Dickinson Diagnostics Inc., GeneOhm Sciences Inc. Also represented by Robert J. Gunther, Jr., Christopher R. Noyes ; William G. McElwain, Thomas Saunders, Washington, DC.
Before Prost, Chief Judge, Reyna and Wallach, Circuit Judges.
Enzo Life Sciences, Inc. ("Enzo") appeals the decision of the U.S. District Court for the District of Delaware granting summary judgment against Enzo and holding that the asserted claims are invalid for lack of enablement. We affirm as to non-enablement and do not reach the other issues presented on appeal.
Deoxyribonucleic acid ("DNA") and ribonucleic acid ("RNA") are nucleic acids. They are made of a series of building blocks, called nucleotides, linked together in a chain. A single nucleotide is made up of a sugar, a phosphate, and a nitrogenous base. DNA nucleotides have one of four nitrogenous bases: adenine (A); guanine (G); cytosine (C); and thymine (T). RNA has the same bases, except it uses uracil (U) instead of thymine (T).
A polynucleotide refers to multiple nucleotides linked together in a chain.1 The nucleotides located at each end of a polynucleotide chain are referred to as terminal nucleotides. All other nucleotides in a polynucleotide chain are referred to as internal nucleotides.
Two strands of polynucleotides can pair with each other, i.e., hybridize, through hydrogen bonding between the bases on each polynucleotide strand. The bases T and U pair with A, while G pairs with C. This is referred to as complementary base pairing or "Watson-Crick base pairing," and this pairing is how the now-familiar double helix shape is formed. Two polynucleotide strands will hybridize if the arrangement of nucleotides in each strand is such that enough bases can pair with each other. For example, whether two strands will hybridize depends in part on the number of complementary base pairs that exist between the two polynucleotides.
Hybridization techniques are used to detect the presence of certain nucleic acid sequences of interest, i.e., target sequences, such as genetic alterations. In such procedures, scientists use a hybridization "probe"—i.e., a labeled polynucleotide that is hybridizable and remains detectable after hybridization occurs—that is sufficiently complementary to the target sequence. The probe will hybridize with the target sequence if the target sequence is present, and the label on the probe then allows scientists to detect the hybridized probe.
Nucleic acid hybridization was well understood by June 1982, which is the claimed priority date of the patents at issue in this appeal. The prevailing method of labeling probes at that time was via radioactive labeling. Radioactive labeling generally involved replacing certain atoms in the nucleotide sequence with corresponding radioactive isotopes.
Non-radioactive labeling was just developing at the time of the claimed inventions. In 1981, Dr. David Ward and others at Yale University successfully developed a nonradioactive probe by attaching a label to a polynucleotide via a chemical linker at a base position of a nucleotide. See J.A. 4129–33 ( ). Dr. Ward demonstrated that attaching labels at certain positions of the nucleotide ("the Ward positions") would not disrupt the polynucleotide’s ability to hybridize and be detected upon hybridization.
In December 1981, Enzo licensed the exclusive rights to the patent portfolio covering Dr. Ward’s discovery. See J.A. 4258–75. Shortly thereafter, in June 1982, Enzo filed a patent application covering non-radioactive labeling at additional positions on a nucleotide. The two patents in this appeal issued from applications filed in 1995 that claim priority from this 1982 application.
Both patents in this appeal generally relate to the use of non-radioactively labeled polynucleotides in nucleic acid hybridization and detection applications. The patents share the same specification in relevant part. See J.A. 90 n.6.
U.S. Patent No. 6,992,180 ("the ’180 patent") relates to non-radioactive labeling of polynucleotides where the label is attached at the phosphate position of a nucleotide. The claims are not directed to any specific polynucleotide, nor do they focus on the chemistry or linker used to attach a label, the number of labels to attach to a polynucleotide, or where within the polynucleotide to attach those labels. Instead, the claims encompass all polynucleotides with labels attached to a phosphate, as long as the polynucleotide remains hybridizable and detectable upon hybridization. Claim 1 of the ’180 patent is representative:
’180 patent claim 1 (emphases added).
"Sig" represents a signaling moiety (i.e., a label); PM represents a phosphate moiety; SM represents a sugar moiety; and BASE represents a base moiety.
The asserted claims of U.S. Patent No. 8,097,405 ("the ’405 patent") fall into two categories: (1) in situ hybridization claims; and (2) liquid phase hybridization claims.
The in situ hybridization claims (claims 63, 64, 65, 95, 103, 128, and 144) describe a process that uses a probe non-radioactively labeled at any non-Ward position to identify chromosomes. In situ hybridization is where probes are hybridized to a target that is fixed, usually on a glass slide. Claim 64 is exemplary.
The liquid phase hybridization claims (claims 196 and 198) describe a process that uses a non-radioactively labeled probe to hybridize and detect a target sequence in a liquid medium, rather than on a glass slide. These claims cover using probes labeled non-radioactively at any position on the nucleotide, including the three Ward positions. The asserted liquid phase hybridization claims depend from claim 189.
This consolidated appeal involves four district court cases.2 The ’180 patent is at issue in all four cases, while the ’405 patent is at issue only in the cases against Abbott.
In January 2012, Enzo filed suit against Roche Molecular Systems, Inc., Roche Diagnostics Corp., Roche Diagnostics Operations, Inc., and Roche Nimblegen, Inc. (collectively, "Roche") alleging infringement of the ’180 patent. J.A. 1212–16 (Compl.) (Case No. 1:12-cv-106). In March 2012, Enzo filed separate suits against Becton, Dickinson and Co., Becton Dickinson Diagnostics Inc., and GeneOhm Sciences, Inc. (collectively, "BD"); and Abbott Laboratories and Abbott Molecular, Inc. (collectively, "Abbott") alleging infringement of the ’180 patent. J.A. 2833–36 (Compl.) (Case No. 1:12-cv-275 against BD); J.A. 1964–67 (Compl.) (Case No. 1:12-cv-274 against Abbott). In February 2013, Enzo filed a second suit against Abbott alleging infringement of the ’405 patent. J.A. 3973–77 (Compl.) (Case No. 1:13-cv-225).
In June 2017, in the cases against Roche and BD, the district court denied summary judgment with respect to written description, but granted summary judgment in favor of the defendants, holding that all asserted claims of the ’180 patent were invalid as...
To continue reading
Request your trial-
Baxalta Inc. v. Bayer Healthcare LLC, Civil Action No. 17-1316-RGA
...(finding that the "immense breadth of screening required" constituted undue experimentation); Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc. , 928 F.3d 1340, 1348-49 (Fed. Cir. 2019) (finding the "breadth of the claims" to be "particularly troubling" in light of the unpredictability of......
-
Home Depot U.S.A. v. Lynk Labs.
...not be able to practice the claimed invention without undue experimentation." Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., 928 F.3d 1340, 1345 (Fed. Cir. 2019). Factors to be considered in determining whether a disclosure would require undue experimentation include: (1) the qu......
-
MCRO, Inc. v. Bandai Namco Games Am. Inc.
..., e.g. , Idenix Pharms. LLC v. Gilead Scis. Inc. , 941 F.3d 1149, 1155–56 (Fed. Cir. 2019) ; Enzo Life Scis., Inc. v. Roche Molecular Systems, Inc. , 928 F.3d 1340, 1346–47, 1349 (Fed. Cir. 2019) ; Wyeth & Cordis Corp. v. Abbott Labs. , 720 F.3d 1380, 1384, 1387 (Fed. Cir. 2013) ; Enzo Bioc......
-
Idenix Pharm. LLC v. Gilead Scis. Inc.
...enablement. Enzo Biochem, Inc. v. Calgene, Inc. , 188 F.3d 1362, 1374 (Fed. Cir. 1999) ; see Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc. , 928 F.3d 1340, 1348 (Fed. Cir. 2019) (working example that was "insufficient to enable the breadth of the claims here, especially in light of th......
-
Patent Antibody Case Law Continues To Mature
...include: Wyeth & Cordis Corp. v. Abbott Labs., 720 F.3d 1380 (Fed. Cir. 2013), Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc., 928 F.3d 1340 (Fed. Cir. 2019) and Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149 (Fed. Cir. 2019). Then, in the past two years, cases filed in the Dis......
-
Patent Antibody Case Law Continues To Mature
...include: Wyeth & Cordis Corp. v. Abbott Labs., 720 F.3d 1380 (Fed. Cir. 2013), Enzo Life Scis., Inc. v. Roche Molecular Sys., Inc., 928 F.3d 1340 (Fed. Cir. 2019) and Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149 (Fed. Cir. 2019). Then, in the past two years, cases filed in the Dis......
-
Biotechnology At The Supreme Court'Will The U.S. Government Back Amgen's Petition?
...Amgen's patent claims were analogous to those found invalid as a matter of law at summary judgement in Wyeth (720 F.3d 1380) and Enzo (928 F.3d 1340), and in Idenix (941 F.3d 1149) based on a Rule 50 motion. In each of these cases, broad functional claims were found invalid based on a lack ......
-
A New Frontier in Patent Bar Ethics?
...the patent’s priority date constituted an anticipatory prior use. Enablement Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. , 928 F.3d 1340, 2019 U.S.P.Q.2d 249412 (Fed. Cir. 2019). The Federal Circuit upheld the district court’s finding that the claims were invalid for lack of e......
-
An Interview with Li-Hsien (Lily) Rin-Laures
...the patent’s priority date constituted an anticipatory prior use. Enablement Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. , 928 F.3d 1340, 2019 U.S.P.Q.2d 249412 (Fed. Cir. 2019). The Federal Circuit upheld the district court’s finding that the claims were invalid for lack of e......
-
Patenting Nature
...the patent’s priority date constituted an anticipatory prior use. Enablement Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. , 928 F.3d 1340, 2019 U.S.P.Q.2d 249412 (Fed. Cir. 2019). The Federal Circuit upheld the district court’s finding that the claims were invalid for lack of e......
-
Why Open Source Licenses with a Commons Clause May Become Less Common
...the patent’s priority date constituted an anticipatory prior use. Enablement Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. , 928 F.3d 1340, 2019 U.S.P.Q.2d 249412 (Fed. Cir. 2019). The Federal Circuit upheld the district court’s finding that the claims were invalid for lack of e......